Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NSD1
REST API REST API
Homo sapiens
NSD1 is differentially expressed in 246 experiments: 123 organism parts: testis, bone marrow, ... (121 more);, 158 disease states: normal, breast carcinoma, ... (156 more);, 65 cell types 343 cell lines 34 compound treatments and 70 other conditions.
Synonyms FLJ22263, STO, ARA267, KMT3B
Orthologs NSD1 (Gallus gallus)   nsd1b (Danio rerio)   Nsd1 (Rattus norvegicus)   Nsd1 (Mus musculus)   NSD1 (Bos taurus)   nsd1a (Danio rerio)   nsd1 (Xenopus laevis)   NSD1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term histone H3-K36 methylation, histone methyltransferase activity (H4-K20 specific), ligand-dependent nuclear receptor binding, protein binding, histone methylation, transcription corepressor activity, histone methyltransferase activity (H3-K36 specific), metal ion binding, methyltransferase activity, transcription cofactor activity, nucleus, chromatin binding, transferase activity, chromosome, chromatin modification, histone methyltransferase activity, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, histone-lysine N-methyltransferase activity, zinc ion binding, androgen receptor binding, retinoid X receptor binding, gastrulation with mouth forming second, estrogen receptor binding, thyroid hormone receptor binding, retinoic acid receptor binding, histone H4-K20 methylation
InterPro Term Znf_PHD-finger, AWS, Znf_PHD, Post-SET_dom, PWWP, SET_dom
UniProt Accession Q96L73, Q96DQ7, Q9H6B5, Q9H6H8, Q96MN8, D6RA58, D6RA90, D6RE14, D6RBP3, D6RBV9, D6RG26, Q658U6
Gene-Disease Assocation WEAVER SYNDROME, SOTOS SYNDROME, LEUKEMIA, ACUTE MYELOID; AML, BECKWITH-WIEDEMANN SYNDROME; BWS
Search EB-eye ENSG00000165671
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-17189, E-GEOD-22541, E-GEOD-6573, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
SNU1
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-6013, E-GEOD-3202
DU145
2
E-GEOD-17482, E-GEOD-20089
MOLT4
2
E-MTAB-62, E-MTAB-37
HL-60
1
2
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
337 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-4219, ... (35 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-3982, E-GEOD-22373
stromal cell
2
E-MEXP-2034, E-GEOD-3998
primary human mammary epithelial cells
1
E-GEOD-29119
epithelioid malignant mesothelioma (MM)
1
E-GEOD-21750
n/a
1
E-MTAB-24
granulopoietic
1
E-GEOD-9894
59 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-MEXP-2280, E-GEOD-16363, E-MTAB-680, ... (50 experiments)

Factor Value U/D Experiments
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
choriocarcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MTAB-37
melanoma
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
1
2
E-MTAB-37, E-GEOD-5823, E-MEXP-1331
breast carcinoma
1
2
E-MTAB-37, E-GEOD-7307, E-GEOD-5823
152 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-1417, E-TABM-782, E-GEOD-3720, E-TABM-868, ... (23 experiments)

Factor Value U/D Experiments
5-aza-2'-deoxycytidine
2
2
E-MEXP-1269, E-GEOD-5230
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
untreated
1
E-GEOD-15389
phorbol 12-myristate 13-acetate + ionomycin
1
E-GEOD-3720
NaOH
1
E-MEXP-2590
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-GEOD-5230
28 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
31
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-MEXP-2280, E-GEOD-21138

Environmental stress
studied in E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-6432, E-GEOD-7011, E-MEXP-2657, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-16363, E-GEOD-430, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-19330, E-GEOD-10896

RNAi
studied in E-MEXP-101, E-MEXP-1857, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16193, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.401 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM